RARE DISEASE
Ataxia with vitamin E deficiency
Ataxia with vitamin E deficiency
Ataxia with vitamin E deficiency
Synonyms: AVED, Ataxia with isolated vitamin E deficiency, Familial isolated vitamin E deficiency, Friedreich-like ataxia, Isolated vitamin E deficiency
Synonyms: AVED, Ataxia with isolated vitamin E deficiency, Familial isolated vitamin E deficiency, Friedreich-like ataxia, Isolated vitamin E deficiency
Synonyms: AVED, Ataxia with isolated vitamin E deficiency, Familial isolated vitamin E deficiency, Friedreich-like ataxia, Isolated vitamin E deficiency
Drug discovery
1
drug
With orphan designation
Overview
Ataxia with Vitamin E Deficiency (AVED) is an autosomal recessive neurodegenerative disorder caused by mutations in the TTPA gene, impairing α-tocopherol transfer protein function. This results in severe vitamin E deficiency despite normal dietary intake, leading to progressive cerebellar ataxia, dysarthria, peripheral neuropathy, and retinitis pigmentosa. Symptoms typically manifest between ages 5–15, with untreated cases progressing to wheelchair dependence. Diagnosis requires serum vitamin E testing (lipid-adjusted levels) and genetic confirmation. High-dose vitamin E supplementation (800–1,500 mg/day) stabilizes or improves symptoms if initiated early [1][2][9][13].
Burden
Untreated patients develop severe disability (e.g., loss of ambulation within 8–20 years) [13][19].
Residual deficits (proprioceptive loss, dysarthria) persist even with treatment [9][15].
Economic/social burdens include chronic care needs and frequent misdiagnosis (e.g., Friedreich ataxia) [9][13].
Therapies
Lifelong high-dose vitamin E (α-tocopherol): 800–1,500 mg/day orally; doses up to 40 mg/kg/day in children [3][7][9].
Early treatment prevents progression; delayed intervention may only halt decline [9][15].
Monitoring: Annual neurologic exams and serum vitamin E levels to ensure adequacy (>12 µmol/L) [7][13].
Categories: rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases, rare ophthalmic disorders
Research Papers
103 drug discovery papers about Ataxia with vitamin E deficiency, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
103 drug discovery papers about Ataxia with vitamin E deficiency, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-06-09 | Analysis of clinical pedigree characteristics in Chinese patients with ataxia with vitamin E deficiency.
The clinical and genetic features of ataxia with isolated vitamin E deficiency (AVED) patients in Chinese are remain not well understood. We enrolled 120 unrelated probands with clinically suspected autosomal recessive cerebellar ataxia (ARCA) at the Department of Neurology, China-Japan Friendship Hospital between 2014 and 2024. all probands underwent Whole-exome sequencing (WES), with candidate variants validated by Sanger sequencing and family cosegregation analysis. In silico pathogenicity analysis, including protein structure homology modeling and multispecies conservation analysis, was performed for novel variants. Plasma vitamin E levels were measured using high-performance liquid chromatography with diode array detection(HPLC-DAD). We identified 4 probands with biallelic TTPA variants, accounting for 3.33% of the ARCA cohort. Three probands were from consanguineous families, and 1 was from non- consanguineous family. The median age at onset was 15years (range 14-23years), with gait instability/ataxia as the universal initial symptom. Core clinical features included cerebellar ataxia (4/4), dysarthria (4/4), areflexia (2/4), scoliosis (4/4), foot deformity (3/4), and head titubation (3/4). Brain MRI revealed cerebellar atrophy in 3 patients, and all had markedly reduced serum vitamin E levels. We identified 2 novel missense variants (c.265C>A(p.P89T) and c.790A>G(p.M264V)). All patients received high-dose vitamin E supplementation, with 3/4 improved ataxia symptoms at 2-years follow-up. Our findings expand the clinical and genetic spectrum of AVED in China and support early evaluation of plasma vitamin E status and TTPA variants in patients with unexplained sporadic or recessive ataxia, as well as proactive screening of siblings and other at-risk relatives, even before symptom onset.
2026-05-21 | Ataxia With Vitamin E Deficiency Syndrome and a Novel TTPA Variant: A Paired Case Report.
Ataxia with vitamin E deficiency (AVED) is a chronic progressive syndrome with low vitamin E levels, caused by biallelic pathogenic variants in the alpha-tocopherol transfer protein (TTPA) gene on chromosome 8q13.1. According to family segregation studies, we describe a novel putative variant in compound heterozygosity with a known pathogenic variant. Clinical and instrumental evaluations were performed at our Neuromuscular Unit. Two siblings had been experiencing clumsiness, which later evolved into progressive gait unsteadiness, with falls and dysarthria. Brain MRI, EMG, and nerve conduction studies were inconclusive, but focused clinical exome sequencing revealed biallelic variants in the TTPA gene in both, the pathogenetic maternally inherited variant c.513_514insTT (p.Thr172Leufs*5) on exon 3 and the previously undescribed paternally inherited variant c.158T > C (p.Leu53Pro) on exon 1. Their plasma vitamin E levels were low (<1.7 mg/L). Their relatives carried 1 single variant each, with normal vitamin E levels. After 6 months of oral vitamin supplementation with a laboratory response, disease progression has stopped, although their neurologic examination has not clearly ameliorated. Exome sequencing identified a new potentially pathogenic variant in AVED, an ultra-rare but treatable cause of inherited ataxia. We recommend prompt vitamin E supplementation in patients with AVED.
2025-11-14 | Systemic Mechanistic Framework of the Keyora Multi-Vitamin & Mineral Matrix: Metabolic, Antioxidant, and Neuro-Endocrine Axes in Human Nutritional Homeostasis
Abstract Micronutrient deficiency remains a pervasive but underappreciated driver of chronic disease, even in populations with adequate calorie intake. Epidemiological data show that low or marginal intakes of vitamin D, folate, iron, zinc, magnesium, and other key micronutrients are common worldwide and are associated with metabolic syndrome, type 2 diabetes mellitus, cardiovascular dysfunction, neurocognitive decline, mood and anxiety disorders, sleep disturbances, immune dysregulation, and impaired reproductive health. Beyond classical deficiency syndromes, subtle but persistent insufficiency disrupts mitochondrial bioenergetics, antioxidant defenses, and neuro–endocrine–immune communication, creating a biochemical milieu that accelerates inflammatory and oxidative aging. In this context, the present work develops a systems-level framework for understanding how a defined set of 13 vitamins (A, D₃, E, K₁, C, thiamine, riboflavin, niacin, vitamin B₆, folate, vitamin B₁₂, biotin, pantothenic acid) and 7 minerals (calcium, magnesium, iron, zinc, copper, manganese, selenium) can be organized into an integrated “Keyora Multi-Vitamin & Mineral Matrix.” This matrix is mapped onto three interconnected mechanistic axes: a Metabolic–Mitochondrial Axis that sustains ATP generation, substrate utilization, insulin sensitivity, and physical and cognitive performance; an Antioxidant–Redox Axis that coordinates enzymatic and non-enzymatic defenses against reactive oxygen and nitrogen species, preserving vascular, neural, dermal, and genomic integrity; and a Neuro–Endocrine–Immune Axis that couples neurotransmitter balance, HPA/HPG-axis regulation, and immune competence. Across these axes, the paper synthesizes physiological and clinical evidence linking micronutrient patterns to disease-specific pathways in metabolic syndrome and type 2 diabetes mellitus, cardiovascular disease, neurocognitive decline and fatigue, depression, anxiety, and sleep disorders, Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD), menopausal symptoms and infertility, osteoporosis, sarcopenia and musculoskeletal degeneration, immune vulnerability, and skin and hair aging. Rather than treating vitamins and minerals as isolated agents, the Keyora Matrix is positioned as a coherent biochemical architecture in which nutrient clusters (e.g., B-complex plus magnesium and iron/copper; vitamin C–vitamin E–selenium–zinc; folate/B₁₂/B₆ plus vitamin D₃ and magnesium) act on shared pathways. By articulating this tri-axis model, the paper addresses a key gap between reductionist micronutrient research and the complex clinical reality of multimorbidity. It proposes a translational scaffold for designing and evaluating multi-nutrient formulations as foundational adjuncts in metabolic medicine, cardiovascular prevention, nutritional psychiatry, reproductive endocrinology, dermatology, and healthy aging. The framework is intended to guide both future mechanism-based clinical trials and precision nutrition strategies that move from simple deficiency correction toward systemic nutritional optimization and restoration of biochemical coherence.
2025-05-09 | Dietary and lifestyle interventions for the management of hereditary ataxias.
Hereditary ataxia (HA) is a diverse group of rare inherited neurological disorders characterised by cerebellar impairment and the progressive degeneration of spinocerebellar tracts and the spinal cord. These conditions manifest predominantly as unsteady gait, speech difficulties, dysphagia and motor skill impairment. The complex genetic causes and varied disease mechanisms underlying HA contribute to the multi-systemic symptoms which pose challenges in developing targeted effective treatments. Currently, available options for HA primarily focus on symptomatic management, highlighting a critical need for complementary therapeutic strategies, such as dietary and lifestyle interventions. This review explains recent findings on dietary and nutraceutical interventions, as well as lifestyle modifications such as exercise and rehabilitation programs for HA. It outlines common types of HA, including Friedreich ataxia, spinocerebellar ataxias, ataxia with vitamin E deficiency, ataxia-telangiectasia, and studies on a mixed cohort of patients with HA. The current management options, therapeutic implications of findings from pre-clinical and clinical data and future directions to advance the treatment of HA will also be discussed. The integration of nutraceuticals and rehabilitation programs with current methods of symptomatic management is encouraged for the holistic treatment of HA. These interventions will complement the use of various technological aids with the support of a multidisciplinary health and medical team to improve monitoring of the health status and disease progression of affected individuals; thus facilitating early treatment and an optimised clinical outcome.
2025-02-18 | Unique Effect of the High-Fat Meal on the Pharmacokinetics of Omaveloxolone Explained by Physiologically Based Biopharmaceutics Modeling
Objectives: Omaveloxolone is a nuclear factor (erythroid-derived 2)-like 2 activator approved in the US and EU for the treatment of Friedreich ataxia in patients aged ≥16 years. It is approved at a dosage of 150 mg administered orally once daily on an empty stomach. Food-drug interactions can potentially alter the pharmacokinetic (PK) parameters of an oral drug, which may affect its efficacy and/or safety profile. Physiologically based biopharmaceutics modeling (PBBM) enables prediction of the PK profiles of oral drugs by integrating drug physicochemical properties and formulation factors with system physiological parameters. A PBBM was developed to predict and explain the effect of the US Food and Drug Administration high-fat meal on the PK of omaveloxolone. Methods: The PBBM was developed using physicochemical, dissolution, bile salt solubilization, precipitation, permeability, and in vitro and in vivo metabolism data. It was then validated across 9 distinct clinical scenarios that evaluated the impact of food, dose proportionality, and drug-drug interactions. Sensitivity analyses were performed to identify the parameters that could impact the absorption and metabolism of omaveloxolone in the fasted state. Results: The model’s predictive ability was evaluated based on the model’s performance indicators of maximum plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC), which met predefined acceptance criteria across all analyzed clinical scenarios. Key parameters influencing the PK of omaveloxolone included bile salt solubilization, maximum rate of reaction of CYP3A4, particle size distribution, and permeability. The PBBM predicted a 350% increase in Cmax, with only a 15% increase in the AUC; this is consistent with clinical study findings. The effect of a high-fat meal on the PK of omaveloxolone is unique, as it differs from the linear correlation between Cmax and AUC ratios reported for other compounds from 323 food effect studies.[1-6] The PBBM showed that in vivo omaveloxolone absorption is solubility and dissolution rate limited. In the fed state, bile salt solubilization resulted in more rapid dissolution, leading to enhanced drug absorption in the upper gastrointestinal tract compared with the fasted state. Consequently, there was an increase in first-pass gut extraction, which explains a large transient elevation in Cmax without a corresponding increase in AUC. Conclusions: By mechanically integrating solubility and dissolution into PBBM, the unique impact of a high-fat meal on the PK profile of omaveloxolone was accurately anticipated. These findings reinforce the drug label recommendations on administration of omaveloxolone on an empty stomach. PBBM has the potential to predict the impact of food on drug PK and possibly eliminates the need for a clinical study.Citations: [1] Singh BN, Malhotra BK. Clin Pharmacokinet. 2004;43(15):1127-1156.[2] Qin H, et al. Basic Clin Pharmacol Toxicol. 2022;130(2):268-276.[3] Riedmaier AE, et al. AAPS J. 2020;22(6):123.[4] Omachi F, et al. J Pharm Health Care Sci. 2019;5:26.[5] Kesisoglou F, et al. AAPS J. 2023;25(4):60.[6] Li M, et al. CPT Pharmacometrics Syst Pharmacol. 2018;7(2):82-89.
proteins
2023-12-08 | Human frataxin, the Friedreich ataxia deficient protein, interacts with mitochondrial respiratory chain
Abstract Friedreich ataxia (FRDA) is a rare, inherited neurodegenerative disease caused by an expanded GAA repeat in the first intron of the FXN gene, leading to transcriptional silencing and reduced expression of frataxin. Frataxin participates in the mitochondrial assembly of FeS clusters, redox cofactors of the respiratory complexes I, II and III. To date it is still unclear how frataxin deficiency culminates in the decrease of bioenergetics efficiency in FRDA patients’ cells. We previously demonstrated that in healthy cells frataxin is closely attached to the mitochondrial cristae, which contain both the FeS cluster assembly machinery and the respiratory chain complexes, whereas in FRDA patients’ cells with impaired respiration the residual frataxin is largely displaced in the matrix. To gain novel insights into the function of frataxin in the mitochondrial pathophysiology, and in the upstream metabolic defects leading to FRDA disease onset and progression, here we explored the potential interaction of frataxin with the FeS cluster-containing respiratory complexes I, II and III. Using healthy cells and different FRDA cellular models we found that frataxin interacts with these three respiratory complexes. Furthermore, by EPR spectroscopy, we observed that in mitochondria from FRDA patients’ cells the decreased level of frataxin specifically affects the FeS cluster content of complex I. Remarkably, we also found that the frataxin-like protein Nqo15 from T. thermophilus complex I ameliorates the mitochondrial respiratory phenotype when expressed in FRDA patient’s cells. Our data point to a structural and functional interaction of frataxin with complex I and open a perspective to explore therapeutic rationales for FRDA targeted to this respiratory complex.
2020-11-04 | Engineering of a functional γ-tocopherol transfer protein
α-tocopherol transfer protein (TTP) was previously reported to self-aggregate into 24-meric spheres (α-TTPS) and to possess transcytotic potency across mono-layers of human umbilical vein endothelial cells (HUVECs). In this work, we describe the characterisation of a functional TTP variant with its vitamer selectivity shifted towards γ-tocopherol. The shift was obtained by introducing an alanine to leucine substitution into the substrate-binding pocket at position 156 through site directed mutagenesis. We report here the X-ray crystal structure of the γ-tocopherol specific particle (γ-TTPS) at 2.24 Å resolution. γ-TTPS features full functionality compared to its α-tocopherol specific parent including self-aggregation potency and transcytotic activity in trans-well experiments using primary HUVEC cells. The impact of the A156L mutation on TTP function is quantified in vitro by measuring the affinity towards γ-tocopherol through micro-differential scanning calorimetry and by determining its ligand-transfer activity. Finally, cell culture experiments using adherently grown HUVEC cells indicate that the protomers of γ-TTP, in contrast to α-TTP, do not counteract cytokine-mediated inflammation at a transcriptional level. Our results suggest that the A156L substitution in TTP is fully functional and has the potential to pave the way for further experiments towards the understanding of α-tocopherol homeostasis in humans.
2012-11-13 | Engineering Tocopherol Selectivity in α-TTP: A Combined In Vitro/In Silico Study
We present a combined in vitro/in silico study to determine the molecular origin of the selectivity of -tocopherol transfer protein (-TTP) towards -tocopherol. Molecular dynamics simulations combined to free energy perturbation calculations predict a binding free energy for -tocopherol to -TTP 8.262.13 kcal mol lower than that of -tocopherol. Our calculations show that -tocopherol binds to -TTP in a significantly distorted geometry as compared to that of the natural ligand. Variations in the hydration of the binding pocket and in the protein structure are found as well. We propose a mutation, A156L, which significantly modifies the selectivity properties of -TTP towards the two tocopherols. In particular, our simulations predict that A156L binds preferentially to -tocopherol, with striking structural similarities to the wild-type--tocopherol complex. The affinity properties are confirmed by differential scanning fluorimetry as well as in vitro competitive binding assays. Our data indicate that residue A156 is at a critical position for determination of the selectivity of -TTP. The engineering of TTP mutants with modulating binding properties can have potential impact at industrial level for easier purification of single tocopherols from vitamin E mixtures coming from natural oils or synthetic processes. Moreover, the identification of a -tocopherol selective TTP offers the possibility to challenge the hypotheses for the evolutionary development of a mechanism for -tocopherol selection in omnivorous animals.
2010-05-01 | ATP-Binding cassette transporter A1 is involved in hepatic α-tocopherol secretion
Vitamin E (α-tocopherol) is an essential fat-soluble nutrient with antioxidant properties. α-Tocopherol transfer protein (α-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma α-tocopherol level by mediating the secretion of α-tocopherol by the liver. However, the mechanisms underlying hepatic α-tocopherol secretion are not fully understood. This study was undertaken to elucidate the mechanism of α-tocopherol re-efflux from hepatocytes, the cells that have the most important role in regulating plasma-α-tocopherol concentrations. From in vitro experiments using [3H]α-tocopheryl acetate and McARH7777 cells that stably express α-tocopherol transfer protein (α-TTP), the following results were obtained. First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased α-tocopherol secretion in a dose-dependent manner. Second, probucol, an antiatherogenic compound reported to be an inactivator of ABCA1 reduced hepatic α-tocopherol secretion. Third, ABCA1-RNAi suppressed hepatic α-tocopherol secretion. In a mouse in vivo experiment, addition of 1% probucol to the diet decreased plasma α-tocopherol concentrations. These results strongly suggest that ABCA1 is substantially involved in hepatic α-tocopherol secretion.
2008-11-27 | Afamin is synthesized by cerebrovascular endothelial cells and mediates alpha-tocopherol transport across an in vitro model of the blood-brain barrier.
Abstract α‐Tocopherol (αTocH), a member of the vitamin E family, is essential for normal neurological function. Despite the importance of αTocH transport into the CNS, transfer mechanisms across the blood–brain barrier (BBB) are not entirely clear. We here investigate whether afamin, a known αTocH‐binding protein, contributes to αTocH transport across an in vitro model of the BBB consisting of primary porcine brain capillary endothelial cells (BCEC) and basolaterally cultured astrocytoma cells. Exogenously added afamin had no adverse effects on BCEC viability or barrier function and was transported across BCEC Transwell cultures. Furthermore, αTocH transport across polarized BCEC cultures to astrocytoma cells is facilitated by afamin, though to a lesser extent than by high‐density lipoprotein‐mediated transport, an essential and in vivo operating αTocH import pathway at the cerebrovasculature. We also demonstrate that porcine BCEC endogenously synthesize afamin. In line with these in vitro findings, afamin was detected by immunohistochemistry in porcine, human postmortem, and mouse brain, where prominent staining was observed almost exclusively in the cerebrovasculature. The demonstration of afamin mRNA expression in isolated brain capillaries suggests that afamin might be a new family member of binding/transport proteins contributing to αTocH homeostasis at the BBB in vivo .
oligonucleotides
2025-01-28 | A TTPA deletion is associated with Retinopathy with Vitamin E Deficiency (RVED) in the English Cocker Spaniel Dog.
Retinopathy with Vitamin E Deficiency (RVED) is a familial disease in the English Cocker Spaniel (ECS) dog breed. Ophthalmic abnormalities observed in RVED-affected ECS include lipofuscin granule deposition within the tapetal fundus and subsequent retinal degeneration resulting in visual deficits. Affected dogs may also exhibit neurological signs that include ataxia and hindlimb proprioceptive deficit. In all cases, circulating plasma concentrations of α-tocopherol are low. This study sought to investigate the genetic basis of RVED in the ECS breed. We undertook a genome-wide association study comprising 30 ECS with normal fundic examinations aged 6 years or older (controls) and 20 diagnosed with RVED (cases) and identified a statistically associated signal on chromosome 29 (Praw = 1.909×10-17). Whole genome sequencing (WGS) of two cases identified a 102bp deletion in exon 1 of the Alpha Tocopherol Transfer Protein gene (TTPA), truncating the protein by 34 amino acids. The c.23_124del variant segregated with RVED in a total of 30 cases and 43 controls. Variants in TTPA are causal for Ataxia with Vitamin E Deficiency (AVED) in humans which is a phenotypically similar disease to RVED. The identification of the canine variant is extremely significant as the availability of a DNA test will allow for identification of presymptomatic dogs and early therapeutic intervention which may prevent development of retinopathy and improve neurological signs. Breeders can also use the DNA test to efficiently eradicate the disease from this breed.
small molecules
2026-06-09 | Analysis of clinical pedigree characteristics in Chinese patients with ataxia with vitamin E deficiency.
The clinical and genetic features of ataxia with isolated vitamin E deficiency (AVED) patients in Chinese are remain not well understood. We enrolled 120 unrelated probands with clinically suspected autosomal recessive cerebellar ataxia (ARCA) at the Department of Neurology, China-Japan Friendship Hospital between 2014 and 2024. all probands underwent Whole-exome sequencing (WES), with candidate variants validated by Sanger sequencing and family cosegregation analysis. In silico pathogenicity analysis, including protein structure homology modeling and multispecies conservation analysis, was performed for novel variants. Plasma vitamin E levels were measured using high-performance liquid chromatography with diode array detection(HPLC-DAD). We identified 4 probands with biallelic TTPA variants, accounting for 3.33% of the ARCA cohort. Three probands were from consanguineous families, and 1 was from non- consanguineous family. The median age at onset was 15years (range 14-23years), with gait instability/ataxia as the universal initial symptom. Core clinical features included cerebellar ataxia (4/4), dysarthria (4/4), areflexia (2/4), scoliosis (4/4), foot deformity (3/4), and head titubation (3/4). Brain MRI revealed cerebellar atrophy in 3 patients, and all had markedly reduced serum vitamin E levels. We identified 2 novel missense variants (c.265C>A(p.P89T) and c.790A>G(p.M264V)). All patients received high-dose vitamin E supplementation, with 3/4 improved ataxia symptoms at 2-years follow-up. Our findings expand the clinical and genetic spectrum of AVED in China and support early evaluation of plasma vitamin E status and TTPA variants in patients with unexplained sporadic or recessive ataxia, as well as proactive screening of siblings and other at-risk relatives, even before symptom onset.
2026-05-21 | Ataxia With Vitamin E Deficiency Syndrome and a Novel TTPA Variant: A Paired Case Report.
Ataxia with vitamin E deficiency (AVED) is a chronic progressive syndrome with low vitamin E levels, caused by biallelic pathogenic variants in the alpha-tocopherol transfer protein (TTPA) gene on chromosome 8q13.1. According to family segregation studies, we describe a novel putative variant in compound heterozygosity with a known pathogenic variant. Clinical and instrumental evaluations were performed at our Neuromuscular Unit. Two siblings had been experiencing clumsiness, which later evolved into progressive gait unsteadiness, with falls and dysarthria. Brain MRI, EMG, and nerve conduction studies were inconclusive, but focused clinical exome sequencing revealed biallelic variants in the TTPA gene in both, the pathogenetic maternally inherited variant c.513_514insTT (p.Thr172Leufs*5) on exon 3 and the previously undescribed paternally inherited variant c.158T > C (p.Leu53Pro) on exon 1. Their plasma vitamin E levels were low (<1.7 mg/L). Their relatives carried 1 single variant each, with normal vitamin E levels. After 6 months of oral vitamin supplementation with a laboratory response, disease progression has stopped, although their neurologic examination has not clearly ameliorated. Exome sequencing identified a new potentially pathogenic variant in AVED, an ultra-rare but treatable cause of inherited ataxia. We recommend prompt vitamin E supplementation in patients with AVED.
2025-11-14 | Systemic Mechanistic Framework of the Keyora Multi-Vitamin & Mineral Matrix: Metabolic, Antioxidant, and Neuro-Endocrine Axes in Human Nutritional Homeostasis
Abstract Micronutrient deficiency remains a pervasive but underappreciated driver of chronic disease, even in populations with adequate calorie intake. Epidemiological data show that low or marginal intakes of vitamin D, folate, iron, zinc, magnesium, and other key micronutrients are common worldwide and are associated with metabolic syndrome, type 2 diabetes mellitus, cardiovascular dysfunction, neurocognitive decline, mood and anxiety disorders, sleep disturbances, immune dysregulation, and impaired reproductive health. Beyond classical deficiency syndromes, subtle but persistent insufficiency disrupts mitochondrial bioenergetics, antioxidant defenses, and neuro–endocrine–immune communication, creating a biochemical milieu that accelerates inflammatory and oxidative aging. In this context, the present work develops a systems-level framework for understanding how a defined set of 13 vitamins (A, D₃, E, K₁, C, thiamine, riboflavin, niacin, vitamin B₆, folate, vitamin B₁₂, biotin, pantothenic acid) and 7 minerals (calcium, magnesium, iron, zinc, copper, manganese, selenium) can be organized into an integrated “Keyora Multi-Vitamin & Mineral Matrix.” This matrix is mapped onto three interconnected mechanistic axes: a Metabolic–Mitochondrial Axis that sustains ATP generation, substrate utilization, insulin sensitivity, and physical and cognitive performance; an Antioxidant–Redox Axis that coordinates enzymatic and non-enzymatic defenses against reactive oxygen and nitrogen species, preserving vascular, neural, dermal, and genomic integrity; and a Neuro–Endocrine–Immune Axis that couples neurotransmitter balance, HPA/HPG-axis regulation, and immune competence. Across these axes, the paper synthesizes physiological and clinical evidence linking micronutrient patterns to disease-specific pathways in metabolic syndrome and type 2 diabetes mellitus, cardiovascular disease, neurocognitive decline and fatigue, depression, anxiety, and sleep disorders, Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD), menopausal symptoms and infertility, osteoporosis, sarcopenia and musculoskeletal degeneration, immune vulnerability, and skin and hair aging. Rather than treating vitamins and minerals as isolated agents, the Keyora Matrix is positioned as a coherent biochemical architecture in which nutrient clusters (e.g., B-complex plus magnesium and iron/copper; vitamin C–vitamin E–selenium–zinc; folate/B₁₂/B₆ plus vitamin D₃ and magnesium) act on shared pathways. By articulating this tri-axis model, the paper addresses a key gap between reductionist micronutrient research and the complex clinical reality of multimorbidity. It proposes a translational scaffold for designing and evaluating multi-nutrient formulations as foundational adjuncts in metabolic medicine, cardiovascular prevention, nutritional psychiatry, reproductive endocrinology, dermatology, and healthy aging. The framework is intended to guide both future mechanism-based clinical trials and precision nutrition strategies that move from simple deficiency correction toward systemic nutritional optimization and restoration of biochemical coherence.
2025-05-09 | Dietary and lifestyle interventions for the management of hereditary ataxias.
Hereditary ataxia (HA) is a diverse group of rare inherited neurological disorders characterised by cerebellar impairment and the progressive degeneration of spinocerebellar tracts and the spinal cord. These conditions manifest predominantly as unsteady gait, speech difficulties, dysphagia and motor skill impairment. The complex genetic causes and varied disease mechanisms underlying HA contribute to the multi-systemic symptoms which pose challenges in developing targeted effective treatments. Currently, available options for HA primarily focus on symptomatic management, highlighting a critical need for complementary therapeutic strategies, such as dietary and lifestyle interventions. This review explains recent findings on dietary and nutraceutical interventions, as well as lifestyle modifications such as exercise and rehabilitation programs for HA. It outlines common types of HA, including Friedreich ataxia, spinocerebellar ataxias, ataxia with vitamin E deficiency, ataxia-telangiectasia, and studies on a mixed cohort of patients with HA. The current management options, therapeutic implications of findings from pre-clinical and clinical data and future directions to advance the treatment of HA will also be discussed. The integration of nutraceuticals and rehabilitation programs with current methods of symptomatic management is encouraged for the holistic treatment of HA. These interventions will complement the use of various technological aids with the support of a multidisciplinary health and medical team to improve monitoring of the health status and disease progression of affected individuals; thus facilitating early treatment and an optimised clinical outcome.
2025-02-18 | Unique Effect of the High-Fat Meal on the Pharmacokinetics of Omaveloxolone Explained by Physiologically Based Biopharmaceutics Modeling
Objectives: Omaveloxolone is a nuclear factor (erythroid-derived 2)-like 2 activator approved in the US and EU for the treatment of Friedreich ataxia in patients aged ≥16 years. It is approved at a dosage of 150 mg administered orally once daily on an empty stomach. Food-drug interactions can potentially alter the pharmacokinetic (PK) parameters of an oral drug, which may affect its efficacy and/or safety profile. Physiologically based biopharmaceutics modeling (PBBM) enables prediction of the PK profiles of oral drugs by integrating drug physicochemical properties and formulation factors with system physiological parameters. A PBBM was developed to predict and explain the effect of the US Food and Drug Administration high-fat meal on the PK of omaveloxolone. Methods: The PBBM was developed using physicochemical, dissolution, bile salt solubilization, precipitation, permeability, and in vitro and in vivo metabolism data. It was then validated across 9 distinct clinical scenarios that evaluated the impact of food, dose proportionality, and drug-drug interactions. Sensitivity analyses were performed to identify the parameters that could impact the absorption and metabolism of omaveloxolone in the fasted state. Results: The model’s predictive ability was evaluated based on the model’s performance indicators of maximum plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC), which met predefined acceptance criteria across all analyzed clinical scenarios. Key parameters influencing the PK of omaveloxolone included bile salt solubilization, maximum rate of reaction of CYP3A4, particle size distribution, and permeability. The PBBM predicted a 350% increase in Cmax, with only a 15% increase in the AUC; this is consistent with clinical study findings. The effect of a high-fat meal on the PK of omaveloxolone is unique, as it differs from the linear correlation between Cmax and AUC ratios reported for other compounds from 323 food effect studies.[1-6] The PBBM showed that in vivo omaveloxolone absorption is solubility and dissolution rate limited. In the fed state, bile salt solubilization resulted in more rapid dissolution, leading to enhanced drug absorption in the upper gastrointestinal tract compared with the fasted state. Consequently, there was an increase in first-pass gut extraction, which explains a large transient elevation in Cmax without a corresponding increase in AUC. Conclusions: By mechanically integrating solubility and dissolution into PBBM, the unique impact of a high-fat meal on the PK profile of omaveloxolone was accurately anticipated. These findings reinforce the drug label recommendations on administration of omaveloxolone on an empty stomach. PBBM has the potential to predict the impact of food on drug PK and possibly eliminates the need for a clinical study.Citations: [1] Singh BN, Malhotra BK. Clin Pharmacokinet. 2004;43(15):1127-1156.[2] Qin H, et al. Basic Clin Pharmacol Toxicol. 2022;130(2):268-276.[3] Riedmaier AE, et al. AAPS J. 2020;22(6):123.[4] Omachi F, et al. J Pharm Health Care Sci. 2019;5:26.[5] Kesisoglou F, et al. AAPS J. 2023;25(4):60.[6] Li M, et al. CPT Pharmacometrics Syst Pharmacol. 2018;7(2):82-89.
proteins
2023-12-08 | Human frataxin, the Friedreich ataxia deficient protein, interacts with mitochondrial respiratory chain
Abstract Friedreich ataxia (FRDA) is a rare, inherited neurodegenerative disease caused by an expanded GAA repeat in the first intron of the FXN gene, leading to transcriptional silencing and reduced expression of frataxin. Frataxin participates in the mitochondrial assembly of FeS clusters, redox cofactors of the respiratory complexes I, II and III. To date it is still unclear how frataxin deficiency culminates in the decrease of bioenergetics efficiency in FRDA patients’ cells. We previously demonstrated that in healthy cells frataxin is closely attached to the mitochondrial cristae, which contain both the FeS cluster assembly machinery and the respiratory chain complexes, whereas in FRDA patients’ cells with impaired respiration the residual frataxin is largely displaced in the matrix. To gain novel insights into the function of frataxin in the mitochondrial pathophysiology, and in the upstream metabolic defects leading to FRDA disease onset and progression, here we explored the potential interaction of frataxin with the FeS cluster-containing respiratory complexes I, II and III. Using healthy cells and different FRDA cellular models we found that frataxin interacts with these three respiratory complexes. Furthermore, by EPR spectroscopy, we observed that in mitochondria from FRDA patients’ cells the decreased level of frataxin specifically affects the FeS cluster content of complex I. Remarkably, we also found that the frataxin-like protein Nqo15 from T. thermophilus complex I ameliorates the mitochondrial respiratory phenotype when expressed in FRDA patient’s cells. Our data point to a structural and functional interaction of frataxin with complex I and open a perspective to explore therapeutic rationales for FRDA targeted to this respiratory complex.
2020-11-04 | Engineering of a functional γ-tocopherol transfer protein
α-tocopherol transfer protein (TTP) was previously reported to self-aggregate into 24-meric spheres (α-TTPS) and to possess transcytotic potency across mono-layers of human umbilical vein endothelial cells (HUVECs). In this work, we describe the characterisation of a functional TTP variant with its vitamer selectivity shifted towards γ-tocopherol. The shift was obtained by introducing an alanine to leucine substitution into the substrate-binding pocket at position 156 through site directed mutagenesis. We report here the X-ray crystal structure of the γ-tocopherol specific particle (γ-TTPS) at 2.24 Å resolution. γ-TTPS features full functionality compared to its α-tocopherol specific parent including self-aggregation potency and transcytotic activity in trans-well experiments using primary HUVEC cells. The impact of the A156L mutation on TTP function is quantified in vitro by measuring the affinity towards γ-tocopherol through micro-differential scanning calorimetry and by determining its ligand-transfer activity. Finally, cell culture experiments using adherently grown HUVEC cells indicate that the protomers of γ-TTP, in contrast to α-TTP, do not counteract cytokine-mediated inflammation at a transcriptional level. Our results suggest that the A156L substitution in TTP is fully functional and has the potential to pave the way for further experiments towards the understanding of α-tocopherol homeostasis in humans.
2012-11-13 | Engineering Tocopherol Selectivity in α-TTP: A Combined In Vitro/In Silico Study
We present a combined in vitro/in silico study to determine the molecular origin of the selectivity of -tocopherol transfer protein (-TTP) towards -tocopherol. Molecular dynamics simulations combined to free energy perturbation calculations predict a binding free energy for -tocopherol to -TTP 8.262.13 kcal mol lower than that of -tocopherol. Our calculations show that -tocopherol binds to -TTP in a significantly distorted geometry as compared to that of the natural ligand. Variations in the hydration of the binding pocket and in the protein structure are found as well. We propose a mutation, A156L, which significantly modifies the selectivity properties of -TTP towards the two tocopherols. In particular, our simulations predict that A156L binds preferentially to -tocopherol, with striking structural similarities to the wild-type--tocopherol complex. The affinity properties are confirmed by differential scanning fluorimetry as well as in vitro competitive binding assays. Our data indicate that residue A156 is at a critical position for determination of the selectivity of -TTP. The engineering of TTP mutants with modulating binding properties can have potential impact at industrial level for easier purification of single tocopherols from vitamin E mixtures coming from natural oils or synthetic processes. Moreover, the identification of a -tocopherol selective TTP offers the possibility to challenge the hypotheses for the evolutionary development of a mechanism for -tocopherol selection in omnivorous animals.
2010-05-01 | ATP-Binding cassette transporter A1 is involved in hepatic α-tocopherol secretion
Vitamin E (α-tocopherol) is an essential fat-soluble nutrient with antioxidant properties. α-Tocopherol transfer protein (α-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma α-tocopherol level by mediating the secretion of α-tocopherol by the liver. However, the mechanisms underlying hepatic α-tocopherol secretion are not fully understood. This study was undertaken to elucidate the mechanism of α-tocopherol re-efflux from hepatocytes, the cells that have the most important role in regulating plasma-α-tocopherol concentrations. From in vitro experiments using [3H]α-tocopheryl acetate and McARH7777 cells that stably express α-tocopherol transfer protein (α-TTP), the following results were obtained. First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased α-tocopherol secretion in a dose-dependent manner. Second, probucol, an antiatherogenic compound reported to be an inactivator of ABCA1 reduced hepatic α-tocopherol secretion. Third, ABCA1-RNAi suppressed hepatic α-tocopherol secretion. In a mouse in vivo experiment, addition of 1% probucol to the diet decreased plasma α-tocopherol concentrations. These results strongly suggest that ABCA1 is substantially involved in hepatic α-tocopherol secretion.
2008-11-27 | Afamin is synthesized by cerebrovascular endothelial cells and mediates alpha-tocopherol transport across an in vitro model of the blood-brain barrier.
Abstract α‐Tocopherol (αTocH), a member of the vitamin E family, is essential for normal neurological function. Despite the importance of αTocH transport into the CNS, transfer mechanisms across the blood–brain barrier (BBB) are not entirely clear. We here investigate whether afamin, a known αTocH‐binding protein, contributes to αTocH transport across an in vitro model of the BBB consisting of primary porcine brain capillary endothelial cells (BCEC) and basolaterally cultured astrocytoma cells. Exogenously added afamin had no adverse effects on BCEC viability or barrier function and was transported across BCEC Transwell cultures. Furthermore, αTocH transport across polarized BCEC cultures to astrocytoma cells is facilitated by afamin, though to a lesser extent than by high‐density lipoprotein‐mediated transport, an essential and in vivo operating αTocH import pathway at the cerebrovasculature. We also demonstrate that porcine BCEC endogenously synthesize afamin. In line with these in vitro findings, afamin was detected by immunohistochemistry in porcine, human postmortem, and mouse brain, where prominent staining was observed almost exclusively in the cerebrovasculature. The demonstration of afamin mRNA expression in isolated brain capillaries suggests that afamin might be a new family member of binding/transport proteins contributing to αTocH homeostasis at the BBB in vivo .
oligonucleotides
2025-01-28 | A TTPA deletion is associated with Retinopathy with Vitamin E Deficiency (RVED) in the English Cocker Spaniel Dog.
Retinopathy with Vitamin E Deficiency (RVED) is a familial disease in the English Cocker Spaniel (ECS) dog breed. Ophthalmic abnormalities observed in RVED-affected ECS include lipofuscin granule deposition within the tapetal fundus and subsequent retinal degeneration resulting in visual deficits. Affected dogs may also exhibit neurological signs that include ataxia and hindlimb proprioceptive deficit. In all cases, circulating plasma concentrations of α-tocopherol are low. This study sought to investigate the genetic basis of RVED in the ECS breed. We undertook a genome-wide association study comprising 30 ECS with normal fundic examinations aged 6 years or older (controls) and 20 diagnosed with RVED (cases) and identified a statistically associated signal on chromosome 29 (Praw = 1.909×10-17). Whole genome sequencing (WGS) of two cases identified a 102bp deletion in exon 1 of the Alpha Tocopherol Transfer Protein gene (TTPA), truncating the protein by 34 amino acids. The c.23_124del variant segregated with RVED in a total of 30 cases and 43 controls. Variants in TTPA are causal for Ataxia with Vitamin E Deficiency (AVED) in humans which is a phenotypically similar disease to RVED. The identification of the canine variant is extremely significant as the availability of a DNA test will allow for identification of presymptomatic dogs and early therapeutic intervention which may prevent development of retinopathy and improve neurological signs. Breeders can also use the DNA test to efficiently eradicate the disease from this breed.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Ataxia with vitamin E deficiency.
1 orphan drug designation for Ataxia with vitamin E deficiency.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Tocophersolan oral solution (vitamin E-tpgs) | — | FDA | 1988-04-15 | — | Sterling Winthrop |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.